GlassScriptPhysician profile
Stephen F Serbin
NPI 1992715684
$5,519.25
in general payments reported to CMS, 2019-2025
31 companies · $871 in 2025
The $871 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $526 · 2020: $453 · 2021: $1,103 · 2022: $941 · 2023: $650 · 2024: $976 · 2025: $871.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,497.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,496.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,876.38 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $789.26 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $494.73 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Esperion Therapeutics, INC. | $320.77 | 2020-2025 | Nexletol |
| Amgen INC. | $273.52 | 2019-2025 | Repatha, Otezla, Otezla |
| Phathom Pharmaceuticals, INC. | $271.58 | 2023-2024 | Voquezna |
| Amarin Pharma, INC. | $222.21 | 2019-2022 | |
| Dexcom, INC. | $149.67 | 2021-2024 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $146.93 | 2022-2023 | |
| Abbott Laboratories | $104.51 | 2019-2024 | Freestyle Libre 2, Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $99.08 | 2019-2024 | Jardiance |
| Glaxosmithkline, LLC. | $82.38 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $79.61 | 2020-2025 | Zoryve |
| Bayer Healthcare Pharmaceuticals INC. | $69.49 | 2021-2024 | |
| Pfizer INC. | $67.02 | 2021-2025 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $55.83 | 2020-2021 | |
| Harmony Biosciences LLC | $55.10 | 2025 | |
| Renalytix Ai, INC. | $46.26 | 2022 | |
| Nestle Healthcare Nutrition INC. | $41.56 | 2021 | |
| Janssen Pharmaceuticals, INC | $38.21 | 2020 | |
| Abiomed | $35.00 | 2025 | |
| Vanda Pharmaceuticals INC. | $27.78 | 2019 | |
| Eisai INC. | $27.31 | 2021 | |
| Astellas Pharma US INC | $25.75 | 2024 | Veozah |
| Alnylam Pharmaceuticals INC. | $20.65 | 2021 | |
| Jazz Pharmaceuticals INC. | $20.03 | 2019 | |
| Medtronic, INC. | $19.99 | 2024 | Intellis Adaptivestim |
| Sanofi Pasteur INC. | $16.39 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.69 | 2020 | |
| Abbvie INC. | $13.44 | 2022 | |
| Sanofi-Aventis U.S. LLC | $13.12 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Serbin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.